Clinical Trials for Mesothelioma Patients: Immunotoxin Therapy

Read about a current clinical trial being conducted to study the effects of Immunotoxin Therapy for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, the study is currently being conducted only in Zurich, Switzerland.

Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery

Rationale: Immunotoxins can find tumor cells and kill them without harming normal cells. Drugs used in chemotherapy, such as pemetrexed and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with immunotoxin therapy may kill more malignant mesothelioma cells.

Purpose: This phase I trial is studying the side effects and best dose of immunotoxin therapy when given together with pemetrexed and cisplatin in treating patients with malignant pleural mesothelioma that cannot be removed by surgery.

Requisite Conditions: Malignant Mesothelioma

Intervention: Drugs: SS1(dsFv)-PE38 immunotoxin; cisplatin; pemetrexed disodium Procedures: chemotherapy; immunoenzyme technique; immunohistochemistry staining method; immunotoxin therapy; pharmacological study; quality-of-life assessment

Study Design and Type: Phase I Interventional; Treatment, Non-Randomized, Open Label, Active Control

Official Title: A Phase I, Single Center, Dose-Escalation Study of CAT-5001 Administered Concurrently With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney